A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC

Provencio, M.Spicer, J.Garrido, P.Trigo Perez, J. M.Viteri, S.Bosch-Barrera, J.Insa, A.Felip, E.De Castro Carpeno, J.Coart, E.Schmidt, E.Christiansen, A.Andersen, M. HaldZocca, M.Ehrnrooth, E.Paz-Aras, L.2025-01-072025-01-072019-10-011556-0864https://hdl.handle.net/10668/26948enNSCLCVaccinePembrolizumabA Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLCconference outputopen access10.1016/j.jtho.2019.08.13561556-1380http://www.jto.org/article/S1556086419320398/pdf492162203271